Trial Profile
Pharmacokinetics, Safety and Tolerability of BIBW 2992 Administered Orally as 20 mg, 30 mg, 40 mg, and 50 mg Tablets (Final Formulation) to Healthy Male Volunteers in an Open-label, Single Rising Dose, Phase I Trial
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jun 2014
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Breast cancer; Colorectal cancer; Glioblastoma; Glioma; Head and neck cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 28 Jun 2014 New trial record